AKT1 and plasma cell myeloma: PI3K/Akt signaling-dependent EMT has been reported to facilitate resistance to chemotherapy in human multiple myeloma 56, cisplatin resistance in hepatocellular carcinoma cells 57 and TAM resistance in breast cancer cells 58.